CN1357329A - Medicine for treating perennial allergic rhinitis - Google Patents
Medicine for treating perennial allergic rhinitis Download PDFInfo
- Publication number
- CN1357329A CN1357329A CN 01134099 CN01134099A CN1357329A CN 1357329 A CN1357329 A CN 1357329A CN 01134099 CN01134099 CN 01134099 CN 01134099 A CN01134099 A CN 01134099A CN 1357329 A CN1357329 A CN 1357329A
- Authority
- CN
- China
- Prior art keywords
- medicine
- treating
- reaction
- rhinitis
- allergic rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention is one kind of medicine for treating perennial allergic rhinitis. Oral antiallergic medicine chromoglycate sodium, chlorphenamine and Prednisolone acetate and externally used rhinitis treating medicine Fuma liquid are compounded in certain proportion to prepare the medicine for treating allergic rhinitis through local application. The medicine can resist allergic reaction, inhibit excitation of sympathetic nerve, reduce the reaction of nasal mucous membrane to histamine, reduce the pathological reaction of nasal mucous membrane to various irritative damage, inhibit proliferation and exudation of connective tissue and relieve various rhinitis symptoms. It has obvious treating effects and no negative reaction.
Description
One, technical field
The present invention relates to a kind of medicine for the treatment of rhinitis, particularly is a kind of perennial allergic rhinitis's of treatment medicine.
Two, background technology
The perennial allergic rhinitis is the common multiple disease of department of otorhinolaryngology, because the variation of the pollution of air and weather causes and suffers from the state of an illness and show effect repeatedly.Its sickness rate accounts for crowd 15%-20%, and according to Epidemiological study, about 10% patient can concurrent bronchial asthma, because antigen and allergenic quantity are increasing, various environmental factorss can not get control, and its sickness rate has and constantly increases trend.Its clinical manifestation hinders with the nose of stubbornness, rhinocnesmus, sneeze, and the water sample tears are feature, and are very painful.Because the glandular secretion of nasal membrane, the parasympathetic nervous regulation and control are mainly accepted in vasodilation, and this sick morbidity is generally allergy or the parasympathetic nervous irritability that distributes with nasal cavity is too high that direct relation arranged.The tissue of nasal cavity is the spongy tissue that is made of vein blood vessel in addition, than 4～5 times of normal enlargements, hinders so nose occurs under pathologic condition.When a variety of causes stimulates nasal cavity anterior, can cause sneezing reflex, a series of symptom of nose promptly occur.
Present oral antihistamine and antianaphylactic new drug, though be widely used in clinical teldane, loratadine, cetirizine HCl being arranged, with for these medicines control clinical symptoms in various degree such as sweet smell, sodium chromoglicate, Dun Ke, levocabastines, but the weak point of holding time, the influence of taking medicine for a long time is healthy, such as: subjective symptoms can disappear behind the gram injection human body, but the women is easily caused menoxenia, palace blood, endocrine disturbance, local acne of male or sexual hypofunction etc.Other medicines then have drowsiness in various degree symptom, influence work and study.And find no relevant patent by retrieval.
Three, summary of the invention
The purpose of this invention is to provide a kind of energy and improve long-term property allergic effect rhinitis patient's clinical symptoms, therapeutic effect is obvious, does not have the treatment perennial allergic rhinitis's of drowsiness symptom and other untoward reaction medicine.
Technical scheme of the present invention is based on the medication combined use with oral Claritin and external curing rhinitis, takes the mode of local application effectively to treat.
Medicine of the present invention adopts following materials of weight proportions to make medicament:
Sodium chromoglicate 90～110mg
Chlorphenamine 30～50mg
Meticortelone 110～135mg
2% furacilin-ephedrine solution 100ml
Production method of the present invention is:
Powdered sodium chromoglicate, chlorphenamine, meticortelone added in the furacilin-ephedrine solution successively get final product.
Because sodium chromoglicate is an antiallergic class medicine, can suppress sympathetic excitability.
Chlorphenamine can reduce the reaction of body to histamine, antiallergic; Meticortelone then can alleviate body to the pathological reaction that various zest damages cause, suppresses connective tissue proliferation, reduces inflammatory exudation, is mainly used in various anaphylactic diseases.
Nitrofural in the furacilin-ephedrine solution has wider antibacterial action; Ephedrine has the effect of shrinking the nasal cavity blood vessel.
The present invention adopts sodium chromoglicate, chlorphenamine, these three kinds of medication combined uses of antiallergic class of meticortelone, can effectively realize antianaphylaxis, simultaneously can suppress sympathetic excitability, reduce the reaction of nasal membrane to histamine, carry out antiinflammatory, shrink the nasal cavity blood vessel, alleviate the pathological reaction that nasal membrane causes various zest damages, suppress connective tissue proliferation, ooze out, remove the nose resistance, beat spray, rhinocnesmus, snivel symptom.In addition owing to adopt local application's effect fast, can avoid influencing healthy, there are not drowsiness symptom and other untoward reaction, simultaneously easy to carry.
For showing the therapeutic effect of the present invention to the perennial allergic rhinitis, the present invention is through the clinical observation of 630 routine systems, according to the characteristics of local application's asexuality, age, the selection state of an illness and factor affecting.
600 examples that conventional treatments is suitable are matched group.Take test group: on former treatment basis, stop oral anti-allergy class medicine, adopt medicine point nose of the present invention, three times on the one.Matched group: oral anti-allergy class medicine routinely, the method for furacilin-ephedrine solution point nose is treated simultaneously, and wherein antiallergic class drug oral consumption and test group are complementary.The employing same procedure is made regular check on, and the observation period is 10 days.
Clinical test results is as shown in table 1.
Table 1
| Case load | Symptom | ||||||||
| Rhinocnesmus | Sneeze | The nose resistance | Thin nasal discharge | ||||||
| Before | After | Before | After | Before | After | Before | After | ||
| Test group | 630 | ++++ | Do not have (579 people) | ++++ | Do not have (585 people) | ++++ | Do not have (599 people) | ++++ | Do not have (602 people) |
| + (51 people) | + (45 people) | + (31 people) | + (28 people) | ||||||
| Matched group | 600 | ++++ | ++ (480 people) | ++++ | Tremble (490 people) | ++++ | +++(495 people) | ++++ | +++(487 people) |
| + (100 people) | + (70 people) | ++ (56 people) | ++ (86 people) | ||||||
| Do not have (20 people) | Do not have (40 people) | + (49 people) | + (27 people) | ||||||
Through test statistics, adopt medicament of the present invention that 630 rhinitis patients are done therapeutic test, that obtains significant curative effect accounts for 92%, substantially effectively accounts for 6%, always effectively accounts for 98%.
Four, embodiment
Embodiment 1: adopt following proportion raw material to make medicament:
Sodium chromoglicate 90mg chlorphenamine 30mg
Meticortelone 110mg 2% furacilin-ephedrine solution 100ml
Embodiment 2: adopt following proportion raw material to make medicament:
Sodium chromoglicate 100mg chlorphenamine 40mg
Meticortelone 125mg 2% furacilin-ephedrine solution 100ml
Embodiment 3: adopt following proportion raw material to make medicament:
Sodium chromoglicate 110mg chlorphenamine 50mg
Meticortelone 135mg 2% furacilin-ephedrine solution 100ml
With 100 routine patient's clinical trials, its result of use is as shown in table 2:
Table 2
From table 2 gained, therapeutic effect the best of embodiment 2 is a best proportioning of the present invention.
The foregoing description only is used to the present invention is described and does not limit the invention.
Claims (2)
1. medicine for the treatment of the perennial allergic rhinitis is characterized in that adopting following materials of weight proportions to make medicament:
Sodium chromoglicate 90～110mg chlorphenamine 30～50mg
Meticortelone 110～135mg 2% furacilin-ephedrine solution 100ml
2. treatment perennial allergic rhinitis's according to claim 1 medicine is characterized in that wherein the important proportioning of each raw material is:
Sodium chromoglicate 100mg chlorphenamine 40mg
Meticortelone 125mg 2% furacilin-ephedrine solution 100ml
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01134099 CN1357329A (en) | 2001-10-29 | 2001-10-29 | Medicine for treating perennial allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01134099 CN1357329A (en) | 2001-10-29 | 2001-10-29 | Medicine for treating perennial allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1357329A true CN1357329A (en) | 2002-07-10 |
Family
ID=4672231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01134099 Pending CN1357329A (en) | 2001-10-29 | 2001-10-29 | Medicine for treating perennial allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1357329A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288371A (en) * | 2014-10-22 | 2015-01-21 | 孙爱华 | Traditional Chinese medicine composition for treating perennial allergic rhinitis, preparation method and application |
-
2001
- 2001-10-29 CN CN 01134099 patent/CN1357329A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288371A (en) * | 2014-10-22 | 2015-01-21 | 孙爱华 | Traditional Chinese medicine composition for treating perennial allergic rhinitis, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1708311A (en) | Remedy for fibromyalgia | |
| KR20110014199A (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
| CN1850190A (en) | Ointment for treating rhinitis and preparing method | |
| KR20160061960A (en) | Local anesthesia pain-relieving time-delay angent | |
| CN1565541A (en) | Osteodynia alleviating and wind dispelling liniment | |
| CN1357329A (en) | Medicine for treating perennial allergic rhinitis | |
| CN1294930C (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN110013502A (en) | A kind of composition for preventing and treating acute and chronic rhinitis, nasosinusitis | |
| CN1846781A (en) | Medicine for treating chronic pharyngitis | |
| CN1348788A (en) | Medicine for treating chronic pharyngitis and its prepn | |
| US20040167206A1 (en) | Compositions and method for treating affective, painful or allergic disorders | |
| CN1063820A (en) | The manufacture method of tinea unguium dissolving cream | |
| CN101062008A (en) | Anti-crease agent for removing patches and pox | |
| CN101181448A (en) | Oral administration proprietary Chinese medicine for curing facial palsy | |
| CN1236765C (en) | Levoimidazole for treating nasal polyp | |
| CN1733147A (en) | Chinese traditional medicine for curing soft tissue pains and process for preparing the same | |
| CN104666420A (en) | A medicine for treating rhinitis | |
| CN115040600B (en) | Traditional Chinese medicine composition for treating scalp psoriasis | |
| CN1062446C (en) | Anti-allergy disease preparation | |
| CN1277551C (en) | Mint oil preparation for treating obstructive sleep apnea and low ventilation syndrome | |
| CN1286481C (en) | Embrocation for treating allergic rhinitis | |
| CN1288727A (en) | Composite medicine for rhinitis and its application | |
| CN107375422A (en) | Treatment part catarrh symptom liniment and preparation method thereof | |
| CN1306938C (en) | Combination for local use for preventing anti treating ocular disease | |
| CN117797168A (en) | Allergen-isolated nasal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zeng Yongmei Document name: Notice of publication of application for patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zeng Yongmei Document name: Deemed as a notice of withdrawal |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |